Document text
Principal Investigator: Zachary A Bornholdt
Organization: EITR BIOLOGICS, INC.
Fiscal Year: 2023
Award: $283,552
Funding agency: National Institute of Allergy and Infectious Diseases
The magnitude and duration of the ongoing COVID-19 pandemic have underscored the need to
have a well-equipped—and ideally prepositioned—arsenal of antiviral weapons to mount an
adequate public health response. A key lesson is that multiple medical countermeasures (MCMs)
are needed to maintain potency and efficacy in the face of a rapidly evolving virus. Several
approved SARS-CoV-2 vaccines have been paramount to gaining control over the pandemic,
reducing both the number of infections and severity of disease for much of the global population.
Unfortunately, these vaccines provide little to no protection to immunocompromised individuals
who are unable to mount an effective immune response. Half-life extended monoclonal antibodies
(mAbs) offer an attractive alternative, as their long half-life and high potency offer instantaneous
immunity and vaccine-like protection without requiring the generation of a robust immune
response. While >10,000 mAbs and multiple mAb cocktails have been explored over the course
of the pandemic and several advanced as therapeutic candidates, they have largely failed to
maintain potent activity in the face of prevalent antigenic drift within the SARS-CoV-2 spike
protein. Moreover, currently approved vaccines and immunotherapeutics offer no protection from
a related b-CoV, Middle East respiratory syndrome (MERS) virus. While small molecule inhibitors
such as Paxlovid have shown broad in vitro activity against SARS and MERS, significant issues
with COVID-19 rebound following treatment suggest it may not remain efficacious against the
more lethal MERS virus. A recently identified antibody, 1249A8 (renamed AR-703), that
recognizes a unique and highly conserved epitope in the S2 domain of the coronavirus spike
protein offers a potential solution, being refractory to antigenic drift and having broad activity b-
CoV activity, inclusive of SARS and MERS. The goal of the proposal is to maximize the clinical
utility of AR-703 through multidimensional structure-based approach to increase neutralization
potency and expand breadth of AR-703. In parallel, bispecific antibody engineering utilizing a
novel bovine ultra-long CDR3 (UL-CDR3) based bispecific platform technology will be explored
to introduce synergistic neutralization and resist viral escape. The structures of bovine UL-CDR3s
have a demonstrated ability to independently target cryptic highly conserved epitopes, vital to
maintaining efficacy to novel viral variants. Combining AR-703 and pan-b-CoV UL-CDR3 into a
single bispecific would enable dual engagement of highly conserved neutralizing epitopes offering
a potent solution to SARS2 antigenic drift for the immunocompromised while also guarding
against related lethal b-CoVs should they emerge in the future.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><7S Gamma Globulin><Acceleration><Address><Affinity><Antibodies><Antibody Binding Sites><Antigenic Determinants><Antigens><Assay><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Bi-specific antibodies><Bifunctional Antibodies><Binding><Binding Determinants><Bioassay><Biologic Assays><Biologic Products><Biological Agent><Biological Assay><Biological Products><Bispecific Antibodies><Blood Serum><Body Tissues><Bovine Species><CHO Cells><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 S protein><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 vaccine><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID19><COVID19 S protein><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 pandemic><COVID19 public health crisis><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 vaccine><COVID19 virus><CV-19><CV19><Cattle><Cell Line><CellLine><Chinese Hamster Ovary Cell><Clinical><Clinical Treatment Moab><CoV S protein><CoV glycoprotein S><CoV spike glycoprotein><CoV spike protein><CoV-2><CoV2><Common Rat Strains><Coronavirus glycoprotein S><Coronavirus spike protein><Cricetinae><Custom><Dimensions><Dose><Drug Kinetics><Elderly><Epitopes><Evaluation><Formulation><Future><Generations><Genetic Alteration><Genetic Change><Genetic Polymorphism><Genetic defect><Genetics-Mutagenesis><Glycoproteins><Goals><Half-Life><Hamsters><Hamsters Mammals><Hour><IgG><Immune response><Immunity><Immunize><Immunocompromised><Immunocompromised Host><Immunocompromised Patient><Immunoglobulin G><Immunological response><Immunosuppressed Host><Immunotherapeutic agent><Individual><Infection><Lead><MAb Therapeutics><MERS><MERS corona virus><MERS coronavirus><MERS coronavirus disease><MERS virus><MERS-CoV><MERS-CoV disease><Middle East Respiratory Syndrome><Middle East Respiratory Syndrome CoV disease><Middle East Respiratory Syndrome Corona Virus><Middle East Respiratory Syndrome Coronavirus><Middle East Respiratory Syndrome Virus><Middle East Respiratory Syndrome coronavirus disease><Middle East Respiratory Syndrome-CoV><Middle East Respiratory coronavirus><Middle Eastern Respiratory Syndrome><Middle Eastern Respiratory Syndrome CoV disease><Middle Eastern Respiratory Syndrome Corona virus><Middle Eastern Respiratory Syndrome Coronavirus><Middle Eastern Respiratory Syndrome Virus><Middle Eastern Respiratory Syndrome coronavirus disease><Middle Eastern Respiratory Syndrome-CoV><Modeling><Modification><Molecular Interaction><Monoclonal Antibodies><Mutagenesis><Mutagenesis Molecular Biology><Mutation><Names><PBMC><Paratopes><Paxlovid><Pb element><Peripheral Blood Mononuclear Cell><Pharmacokinetics><Phase><Population><Position><Positioning Attribute><Predisposition><Production><Proteins><Public Health><Rat><Rats Mammals><Rattus><Refractory><Resolution><SARS><SARS corona virus 2><SARS coronavirus disease><SARS-CO-V2><SARS-COVID-2><SARS-CoV disease><SARS-CoV-2><SARS-CoV-2 S protein><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 pandemic><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 vaccine><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 epidemic><SARS-CoV2 pandemic><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Serum><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome CoV disease><Severe Acute Respiratory Syndrome coronavirus disease><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Severity of illness><Strains Cell Lines><Structure><Susceptibility><Testing><Therapeutic><Therapeutic Monoclonal Antibodies><Tissues><Toxic effect><Toxicities><Transgenic Mice><Vaccines><Variant><Variation><Viral><Virus><Wuhan coronavirus><advanced age><antibody combining site><antibody engineering><beta CoV><beta coronavirus><betaCoV><betacoronavirus><biologics><biopharmaceutical><biotherapeutic agent><bovid><bovine><bsAb><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus S protein><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><coronavirus spike glycoprotein><cow><cross reactivity><cultured cell line><customs><disease severity><elders><genome mutation><geriatric><group competition><hCoV19><heavy metal Pb><heavy metal lead><high risk group><high risk individual><high risk people><high risk population><host response><immune drugs><immune system response><immune-based therapeutics><immunogen><immunologic therapeutics><immunoresponse><immunosuppressed patient><immunotherapeutics><immunotherapy agent><in vitro activity><in vivo><in vivo evaluation><in vivo testing><late life><later life><lead candidate><mAbs><medical countermeasure><monoclonal Abs><monoclonal antibody drugs><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nCoV2><name><named><naming><nano-molar><nanomolar><nanotherapeutic><novel><older adult><older person><pandemic><pandemic disease><polymorphism><pre-clinical development><preclinical development><prophylactic><resolutions><response><screening><screenings><senior citizen><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><small molecule inhibitor><stem><technology platform><technology system><therapeutic candidate><therapeutic mAbs><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine failure><vaccine for novel coronavirus><variants of concern><weapons><β CoV><β coronavirus><βCoV>